These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 9150695)

  • 41. [Somatostatin analogs in the clinical management of pituitary neoplasms].
    Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
    Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A; Sanno N; Tahara S; Osamura YR
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
    Meyer P; Bohnen NI; Barkan AL; Shapiro B
    Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
    Colao A; Ferone D; Lombardi G; Lastoria S
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.
    Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pituitary imaging using a labelled somatostatin analogue in acromegaly.
    Ur E; Mather SJ; Bomanji J; Ellison D; Britton KE; Grossman AB; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):147-50. PubMed ID: 1348978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
    Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
    Oshino S; Saitoh Y; Kasayama S; Arita N; Ohnishi T; Kohara H; Izumoto S; Yoshimine T
    Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
    de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.
    Plöckinger U; Albrecht S; Mawrin C; Saeger W; Buchfelder M; Petersenn S; Schulz S
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1203-10. PubMed ID: 18198230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide.
    Gonzalez B; Vargas G; Ramirez C; Asa S; Cheng S; Sandoval C; Mercado M
    Endocrinol Nutr; 2014 Dec; 61(10):523-30. PubMed ID: 25008035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues.
    Lauriero F; Pierangeli E; Rubini G; Resta M; D'Addabbo A
    Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
    Plöckinger U; Hoffmann U; Geese M; Lupp A; Buchfelder M; Flitsch J; Vajkoczy P; Jakob W; Saeger W; Schulz S; Dohrmann C
    Eur J Endocrinol; 2012 Feb; 166(2):223-34. PubMed ID: 22065857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
    Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
    J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.